Trial reportBlood2019
Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL.
Trial report in Blood, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
75 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- DA-EPOCH-R improves the prognosis of patients with double-expressor lymphoma: A single-center retrospective study and meta-analysis.Medicine · 2022Pooled it
- Pooled it
- The Efficacy and Toxicity of CNS Prophylaxis in Diffuse Large B-Cell Lymphoma (CLSG-CNS-01): A Randomized, Multicenter, Prospective Phase 3 Trial.Hematological oncology · 2026Trial
- Trial
- Secondary central nervous system involvement in patients with diffuse large B-cell lymphoma treated with rituximab combined CHOP therapy - a supplementary analysis of JCOG0601.Annals of hematology · 2024Trial
- Central nervous system relapse in younger patients with diffuse large B-cell lymphoma: a LYSA and GLA/DSHNHL analysis.Blood advances · 2023Trial
- MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial.The Lancet. Haematology · 2021Trial
- Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis.Blood advances · 2020Trial
- Clinical outcomes, patterns of relapse, and molecular landscape of advanced stage high-grade B-cell lymphoma.Blood advances · 2026Article
- Low Risk of Central Nervous System Relapse Among Patients With T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Despite High-Risk Disease Presentation.European journal of haematology · 2026Article
- Clinical, Biological, and Treatment-Related Predictors of Central Nervous System Relapse in Diffuse Large B-Cell Lymphoma: A Retrospective Cohort Study.Journal of clinical medicine · 2026Article
- Machine learning enhances risk stratification and treatment failure prediction in diffuse large B-cell lymphoma.HemaSphere · 2026Article
- Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study.Blood cancer journal · 2026Article
- Anatomical Localization-Based Analysis of Relapsed Secondary Central Nervous System Aggressive B-Cell Lymphoma (R-SCNSL).Hematological oncology · 2026Article
- Relationship Between the Uric Acid Level and CNS Relapse Risk in Patients with Newly Diagnosed Adult Diffuse Large B Cell Lymphoma.Journal of clinical medicine · 2026Article
- Prognosis and Treatment of Plasmablastic Lymphoma in the United States: A Multicenter Retrospective Study.Research square · 2025Article
- Risk of central nervous system versus systemic relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP: What should we focus on?HemaSphere · 2025Article
- Large B-cell lymphoma (LBCL): EHA Clinical Practice Guidelines for diagnosis, treatment, and follow-up.HemaSphere · 2025Article
- Genomic risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma.Blood research · 2025Article
- Reliable detection of CNS lymphoma-derived circulating tumor DNA in cerebrospinal fluid using multi-biomarker NGS profiling: insights from a real-world study.Biomarker research · 2025Article
15 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central nervous system (CNS) relapse carries a poor prognosis in diffuse large B-cell lymphoma (DLBCL). Integrating biomarkers into the CNS-International Prognostic Index (CNS-IPI) risk model may improve identification of patients at high risk for developing secondary CNS disease. CNS relapse was analyzed in 1418 DLBCL patients treated with obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, prednisone chemotherapy in the phase 3 GOYA study. Cell of origin (COO) was assessed using gene-expression profiling. BCL2 and MYC protein expression was analyzed by immunohistochemistry. The impact of CNS-IPI, COO, and BCL2/MYC dual-expression status on CNS relapse was assessed using a multivariate Cox regression model (data available in n = 1418, n = 933, and n = 688, respectively). High CNS-IPI score (hazard ratio [HR], 4.0; 95% confidence interval [CI], 1.3-12.3;
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.